Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
How long do you continue ATRA during induction in high risk acute promyelocytic leukemia?
Does bone marrow biopsy done at the end of induction factor into your decision?
Related Questions
If using the triplet AMPLIFY regimen with ven/acala/obin upfront, what do you then plan to use in 2nd line treatment of CLL?
For patients with newly diagnosed unmutated CLL how will you decide between BTKi alone vs Ven/BTKi vs Ven/Obin vs Ven/Obin/Acalabrutinib?
Is there therapeutic relevance for FLT3-ITD mutation in relapsed APML?
How do you decide whether to hold acalabrutinib or zanubrutinib in patients with indolent B-cell lymphoma/leukemias in a perioperative/periprocedural setting?
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
How long do you continue ursodiol for VOD prophylaxis after gemtuzumab ozogamicin for good-risk AML
How do you treat patients with T-cell ALL/T-cell lymphoblastic lymphoma who have pre-existing CKD with a CrCl of 30 mL/min or less?
How do you approach c-KIT mutated, core binding factor (CBF) AML?
How would you approach a young, fit patient with suspected CNS involvement with high circulating blasts?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?